Cross-linking of surface IgM or IgD B-cell receptors (BCR) with appropriate anti-Ig antibodies induces IgM(high) or IgD(high) B-cell depletion, respectively. The aim of this paper is to analyze how injections of anti-delta followed by anti-mu monoclonal antibodies (mAb) can deplete and suppress B cells and then induce T-independent type 2 antigen tolerance in adult mice even after treatment is stopped. The experimental protocol consisted of three daily injections of anti-delta mAb followed by repeated injections of anti-mu mAb. It shows that a sequential injection of anti-delta and anti-mu mAb induces B-cell depletion and T-independent type 2 response downregulation. Morever, the T-dependent response is maintained, except for the IgG3 isotype. After clearance of the anti-delta mAb from the circulation, B cells reappear as an IgD(+) IgM(-) B-cell population in the bone marrow (BM) and spleen. The origin of IgD(+) IgM(-) cells was studied in scid mouse transfer models. We show that IgD(+) IgM(-) B cells are not mature cells reexpressing sIgD but BM-derived cells that require a T-cell presence to be developed. The lack of sIgM expression by posttranscriptional regulation and the need of T-cell help for escaping anti-mu negative selection suggest strongly that this population had properties similar to those of anergized B cells. These results support the potential use of sequential injections of anti-delta and anti-mu in the prevention of xenograft rejection.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1006/cimm.2000.1705 | DOI Listing |
Int Immunol
March 2001
Department of Medicine, Iowa City Veterans Administration Medical Center, Iowa City, IA 52242, USA.
In the classic 'two-signal' model for B cell activation, signal 1 through the antigen receptor plus signal 2 through lymphokine receptors and CD40 leads to proliferation, but signal 1 alone leads to tolerance or anergy. In a protocol designed to deliver signal 1 in vitro with anti-delta without signal 2, purified small dense B cells from untreated mice exposed to any of three monoclonal anti-delta antibodies or to polyclonal anti-delta in vitro showed modest S phase entry at 50 microg/ml. In contrast, at low doses (0.
View Article and Find Full Text PDFCurr Top Microbiol Immunol
February 2001
Department of Immunology, American Red Cross Holland Laboratory, Rockville, MD 20855, USA.
Crosslinking of surface immunoglobulin (Ig) receptors with anti-IgM (anti-mu) but not anti-IgD (anti-delta) antibodies causes growth arrest and apoptosis in several extensively characterized B1-like lymphoma cell lines. While anti-mu stimulates a transient increase in c-myc mRNA and protein expression, followed by a rapid decline below the baseline level, anti-delta only causes a moderate increase in the expression of this oncogene, which returns to baseline levels within 24-48 hours. However, signals downstream from anti-delta can be converted into an apoptotic pathway by modulating PI3K activity, suggesting that PI3K is a critical rheostat controlling survival signals in B1 cell lines.
View Article and Find Full Text PDFJ Immunol
February 2001
Department of Immunology, Holland Laboratory of the American Red Cross, Rockville, MD 20855, USA.
Cross-linking of surface Ig receptors with anti IgM (anti-mu heavy chain, anti-mu), but not anti-IgD (anti-delta heavy chain, anti-delta), Abs leads to growth arrest and apoptosis in several extensively characterized B cell lymphomas. By poorly understood mechanisms, both Igs transiently stimulate c-Myc protein expression. However, ultimately, only anti-mu causes a severe loss in c-Myc and a large induction of p27(Kip1) protein expression.
View Article and Find Full Text PDFCell Immunol
October 2000
Experimental Immunology Unit, University of Louvain, Brussels, Belgium.
Cross-linking of surface IgM or IgD B-cell receptors (BCR) with appropriate anti-Ig antibodies induces IgM(high) or IgD(high) B-cell depletion, respectively. The aim of this paper is to analyze how injections of anti-delta followed by anti-mu monoclonal antibodies (mAb) can deplete and suppress B cells and then induce T-independent type 2 antigen tolerance in adult mice even after treatment is stopped. The experimental protocol consisted of three daily injections of anti-delta mAb followed by repeated injections of anti-mu mAb.
View Article and Find Full Text PDFImmunol Rev
August 2000
Department of Immunology, American Red Cross Holland Laboratory, Rockville, Maryland, USA.
A series of B-cell lymphoma lines with an immature phenotype has been used as a model system to study molecular events associated with receptor ligation induced death. B-cell receptor (BCR) cross-linking with antibodies to membrane IgM (but not with anti IgD) induces c-Myc downregulation via nuclear factor kappaB inactivation and p27(Kip1) accumulation in these B lymphomas. Anti-mu-treated cells then undergo G1 arrest and die by apoptosis independent of Fas.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!